Cargando…
The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
Background: Cabazitaxel is a second-generation taxane that is approved for use with concomitant low dose daily prednisone in metastatic castration resistant prostate cancer (mCRPC) after docetaxel failure. Since the role of daily corticosteroids in improving cabazitaxel efficacy or ameliorating its...
Autores principales: | Buonerba, Carlo, Sonpavde, Guru, Vitrone, Francesca, Bosso, Davide, Puglia, Livio, Izzo, Michela, Iaccarino, Simona, Scafuri, Luca, Muratore, Margherita, Foschini, Francesca, Mucci, Brigitta, Tortora, Vincenzo, Pagliuca, Martina, Ribera, Dario, Riccio, Vittorio, Morra, Rocco, Mosca, Mirta, Cesarano, Nicola, Di Costanzo, Ileana, De Placido, Sabino, Di Lorenzo, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604196/ https://www.ncbi.nlm.nih.gov/pubmed/28928853 http://dx.doi.org/10.7150/jca.20040 |
Ejemplares similares
-
Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2016) -
Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
por: Buonerba, Carlo, et al.
Publicado: (2019) -
PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study
por: Bosso, Davide, et al.
Publicado: (2017) -
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial
por: Buonerba, Carlo, et al.
Publicado: (2018) -
Immunotherapy for penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)